Which has higher earnings and valuation, DNLI or EVO?

Evotec has higher revenue and earnings than Denali Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Denali Therapeutics $330.53M 10.88 -$512.54M -$2.88 N/A Evotec $891.97M 0.85 -$117.12M N/A N/A

Does the media refer more to DNLI or EVO?

In the previous week, Denali Therapeutics had 4 more articles in the media than Evotec. MarketBeat recorded 11 mentions for Denali Therapeutics and 7 mentions for Evotec. Denali Therapeutics' average media sentiment score of 0.76 beat Evotec's score of 0.20 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, TLX or EVO?

Telix Pharmaceuticals has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.65 -$7.12M N/A N/A Evotec $891.97M 0.85 -$117.12M N/A N/A

Does the media prefer TLX or EVO?

In the previous week, Evotec had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 7 mentions for Evotec and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.54 beat Evotec's score of 0.20 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, EVO or GPCR?

Evotec has higher revenue and earnings than Structure Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.85 -$117.12M N/A N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Does the media refer more to EVO or GPCR?

In the previous week, Evotec had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 7 mentions for Evotec and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.61 beat Evotec's score of 0.20 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, EVO or CPRX?

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.85 -$117.12M N/A N/A Catalyst Pharmaceuticals $596.96M 6.46 $214.33M $1.74 18.10

Does the media favor EVO or CPRX?

In the previous week, Evotec had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 7 mentions for Evotec and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Evotec's score of 0.20 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Catalyst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, EVO or DYN?

Evotec has higher revenue and earnings than Dyne Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.85 -$117.12M N/A N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is EVO or DYN more profitable?

Dyne Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Dyne Therapeutics N/A -58.28% -46.77%

Does the media favor EVO or DYN?

In the previous week, Dyne Therapeutics had 3 more articles in the media than Evotec. MarketBeat recorded 10 mentions for Dyne Therapeutics and 7 mentions for Evotec. Dyne Therapeutics' average media sentiment score of 0.58 beat Evotec's score of 0.20 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evotec (EVO) Competitors

$2.14 -0.29 (-11.93%)

Closing price 04:00 PM Eastern

Extended Trading

$2.13 -0.01 (-0.23%)

As of 04:10 PM Eastern

Compare

EVO vs. DNLI, TLX, GPCR, CPRX, and DYN

Should you buy Evotec stock or one of its competitors? MarketBeat compares Evotec with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evotec include Denali Therapeutics (DNLI), Telix Pharmaceuticals (TLX), Structure Therapeutics (GPCR), Catalyst Pharmaceuticals (CPRX), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

How does Evotec compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Evotec (NASDAQ:EVO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Evotec	-26.20%	-24.93%	-11.35%

In the previous week, Denali Therapeutics had 4 more articles in the media than Evotec. MarketBeat recorded 11 mentions for Denali Therapeutics and 7 mentions for Evotec. Denali Therapeutics' average media sentiment score of 0.76 beat Evotec's score of 0.20 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Denali Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Evotec has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Denali Therapeutics currently has a consensus price target of $34.75, suggesting a potential upside of 53.42%. Evotec has a consensus price target of $7.00, suggesting a potential upside of 227.10%. Given Evotec's higher possible upside, analysts plainly believe Evotec is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.81
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Evotec has higher revenue and earnings than Denali Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.88	-$512.54M	-$2.88	N/A
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A

Summary

Denali Therapeutics beats Evotec on 9 of the 15 factors compared between the two stocks.

How does Evotec compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Evotec (NASDAQ:EVO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Telix Pharmaceuticals has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Evotec has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

In the previous week, Evotec had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 7 mentions for Evotec and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.54 beat Evotec's score of 0.20 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Telix Pharmaceuticals has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Telix Pharmaceuticals' return on equity of 0.00% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Evotec	-26.20%	-24.93%	-11.35%

5.8% of Evotec shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Telix Pharmaceuticals presently has a consensus price target of $21.00, suggesting a potential upside of 90.56%. Evotec has a consensus price target of $7.00, suggesting a potential upside of 227.10%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Telix Pharmaceuticals has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.65	-$7.12M	N/A	N/A
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A

Summary

Telix Pharmaceuticals beats Evotec on 9 of the 14 factors compared between the two stocks.

How does Evotec compare to Structure Therapeutics?

Evotec (NASDAQ:EVO) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Evotec has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Structure Therapeutics' return on equity of -24.91% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Structure Therapeutics	N/A	-24.91%	-23.67%

Evotec has higher revenue and earnings than Structure Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

5.8% of Evotec shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Evotec had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 7 mentions for Evotec and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.61 beat Evotec's score of 0.20 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Evotec presently has a consensus price target of $7.00, indicating a potential upside of 227.10%. Structure Therapeutics has a consensus price target of $110.55, indicating a potential upside of 118.51%. Given Evotec's higher possible upside, equities research analysts plainly believe Evotec is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Summary

Structure Therapeutics beats Evotec on 8 of the 14 factors compared between the two stocks.

How does Evotec compare to Catalyst Pharmaceuticals?

Evotec (NASDAQ:EVO) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Evotec's net margin of -26.20%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

In the previous week, Evotec had 4 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 7 mentions for Evotec and 3 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.49 beat Evotec's score of 0.20 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evotec currently has a consensus price target of $7.00, suggesting a potential upside of 227.10%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 1.62%. Given Evotec's higher possible upside, research analysts clearly believe Evotec is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Evotec has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

5.8% of Evotec shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Catalyst Pharmaceuticals beats Evotec on 10 of the 15 factors compared between the two stocks.

How does Evotec compare to Dyne Therapeutics?

Evotec (NASDAQ:EVO) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Evotec has higher revenue and earnings than Dyne Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.85	-$117.12M	N/A	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Evotec has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Evotec currently has a consensus price target of $7.00, suggesting a potential upside of 227.10%. Dyne Therapeutics has a consensus price target of $34.17, suggesting a potential upside of 43.68%. Given Evotec's higher probable upside, research analysts plainly believe Evotec is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Dyne Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Dyne Therapeutics	N/A	-58.28%	-46.77%

In the previous week, Dyne Therapeutics had 3 more articles in the media than Evotec. MarketBeat recorded 10 mentions for Dyne Therapeutics and 7 mentions for Evotec. Dyne Therapeutics' average media sentiment score of 0.58 beat Evotec's score of 0.20 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.8% of Evotec shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Dyne Therapeutics beats Evotec on 8 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVO vs. The Competition

Export

Metric	Evotec	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$761.33M	$2.98B	$6.73B	$12.53B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	N/A	18.77	27.01	24.37
Price / Sales	0.85	825.10	584.16	116.84
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	0.83	4.24	10.81	6.34
Net Income	-$117.12M	$64.26M	$3.58B	$330.89M
7 Day Performance	-24.91%	-3.40%	-2.24%	-1.08%
1 Month Performance	-21.32%	2.40%	3.12%	-0.48%
1 Year Performance	-48.06%	20.40%	26.33%	19.89%

Evotec Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVO Evotec	3.3888 of 5 stars	$2.14 -11.9%	$7.00 +227.1%	-40.3%	$761.33M	$891.97M	N/A	4,553	News Coverage Gap Down High Trading Volume
DNLI Denali Therapeutics	3.3105 of 5 stars	$25.49 -1.0%	$34.25 +34.4%	+82.4%	$4.06B	$330.53M	N/A	430	News Coverage Analyst Forecast
TLX Telix Pharmaceuticals	4.5873 of 5 stars	$11.70 -3.7%	$21.13 +80.6%	-31.3%	$3.97B	$803.79M	N/A	1,184	Gap Down
GPCR Structure Therapeutics	2.6236 of 5 stars	$54.18 -1.0%	$110.55 +104.0%	+171.6%	$3.88B	N/A	N/A	136	News Coverage Positive News
CPRX Catalyst Pharmaceuticals	3.8852 of 5 stars	$31.50 0.0%	$32.00 +1.6%	+44.3%	$3.86B	$588.99M	18.10	80	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVO) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evotec (EVO) Competitors

EVO vs. DNLI, TLX, GPCR, CPRX, and DYN

How does Evotec compare to Denali Therapeutics?

Summary

How does Evotec compare to Telix Pharmaceuticals?

Summary

How does Evotec compare to Structure Therapeutics?

Summary

How does Evotec compare to Catalyst Pharmaceuticals?

Summary

How does Evotec compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evotec (EVO) Competitors

EVO vs. DNLI, TLX, GPCR, CPRX, and DYN

How does Evotec compare to Denali Therapeutics?

Do insiders & institutionals hold more shares of DNLI or EVO?

Is DNLI or EVO more profitable?

Does the media refer more to DNLI or EVO?

Which has more risk & volatility, DNLI or EVO?

Do analysts prefer DNLI or EVO?

Which has higher earnings and valuation, DNLI or EVO?

Summary

How does Evotec compare to Telix Pharmaceuticals?

Which has more volatility and risk, TLX or EVO?

Does the media prefer TLX or EVO?

Is TLX or EVO more profitable?

Do insiders & institutionals hold more shares of TLX or EVO?

Do analysts rate TLX or EVO?

Which has preferable earnings & valuation, TLX or EVO?

Summary

How does Evotec compare to Structure Therapeutics?

Which has more volatility & risk, EVO or GPCR?

Is EVO or GPCR more profitable?

Which has higher earnings and valuation, EVO or GPCR?

Do institutionals and insiders have more ownership in EVO or GPCR?

Does the media refer more to EVO or GPCR?

Do analysts rate EVO or GPCR?

Summary

How does Evotec compare to Catalyst Pharmaceuticals?

Which has preferable valuation and earnings, EVO or CPRX?

Is EVO or CPRX more profitable?

Does the media favor EVO or CPRX?

Do analysts prefer EVO or CPRX?

Which has more risk & volatility, EVO or CPRX?

Do insiders and institutionals believe in EVO or CPRX?

Summary

How does Evotec compare to Dyne Therapeutics?

Which has preferable earnings and valuation, EVO or DYN?

Which has more risk and volatility, EVO or DYN?

Do analysts prefer EVO or DYN?

Is EVO or DYN more profitable?

Does the media favor EVO or DYN?

Do institutionals and insiders hold more shares of EVO or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVO vs. The Competition

Evotec Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools